Gail Roboz, MD
Hematology & Oncology · New York, NYNPI 1417044504
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $592,335 of the $738,275 with a category attached, or 80.2%. It is spread thinly across 28 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2019 at $164,581 and has fallen 60.2% since, to $65,539 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $1958.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$168K
- GSK$63K
- Bristol Myers Squibb$52K
- Janssen Research & Development, LLC$50K
- Jazz Pharmaceuticals Inc.$50K
- Janssen Global Services, LLC$46K
- plus $310K from 22 others
Across 619 payments — averaging $12,068 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.1M
- Otsuka Pharmaceutical Co., Ltd.$1.3M
- AbbVie$1.1M
- Pfizer$707K
- Taiho Oncology, Inc.$488K
- Bristol Myers Squibb$250K
- plus $1.5M from 18 others
What the payments were for
- Consulting fees$592,33580%
- Speaking & faculty fees$41,5586%
- Travel & lodging$94,89913%
- Food & beverage$5,5011%
- Education$3,9831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $168,109 |
| GSK | 13 | $62,625 |
| Bristol Myers Squibb | 24 | $52,276 |
| Janssen Research & Development, LLC | 16 | $49,627 |
| Jazz Pharmaceuticals Inc. | 22 | $49,534 |
| Janssen Global Services, LLC | 22 | $45,669 |
| Amgen | 25 | $44,923 |
| Agios Pharmaceuticals, Inc. | 18 | $42,381 |
| Daiichi Sankyo Company LTD | 19 | $34,864 |
| Novartis | 10 | $27,003 |
| E.r. Squibb & Sons, L.L.C. | 11 | $24,553 |
| AstraZeneca(2 entities) | 6 | $23,957 |
| Astrazeneca UK Limited | 2 | $15,090 |
| Pfizer | 6 | $13,858 |
| Daiichi Sankyo Inc. | 11 | $13,002 |
| F. Hoffmann-la Roche AG | 9 | $12,052 |
| Astellas Pharma US Inc | 7 | $9,519 |
| Helsinn Healthcare SA | 2 | $7,500 |
| Blueprint Medicines Corporation | 1 | $7,500 |
| Genentech, Inc. | 4 | $7,463 |
| Y-mabs Therapeutics, Inc. | 1 | $6,750 |
| Gilead | 4 | $3,926 |
| Rigel Pharmaceuticals, Inc. | 3 | $3,889 |
| Geron Corporation | 9 | $3,845 |
| Syndax Pharmaceuticals, Inc. | 2 | $2,532 |
| PTC Therapeutics, Inc. | 2 | $2,367 |
| Servier Pharmaceuticals LLC | 2 | $1,960 |
| Telix Pharmaceuticals | 1 | $1,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$738,275 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 13 | $206 |
| Allopurinol | 14 | $83 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
- Ajai ChariNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.